Celltrion, 490,784 Shares Net Bought by Individuals in Last 5 Days... Stock Price 298,000 KRW (+0.68%)

As of 10:30 AM on the 24th, Celltrion is trading at 298,000 KRW, up 0.68% from the previous day. The trading volume is 531,144 shares, which is about 43.35% of the previous day's volume. Celltrion is known as a manufacturer of protein and biopharmaceutical products.

On February 23, Mi-hwa Seo, a researcher at Yuanta Securities, stated, "With the launch of the Humira biosimilar Uplyma this year, the biosimilar product portfolio will be strengthened to five products. The IND applications for Phase 3 clinical trials of biosimilars for Prolia, Eylea, and Stelara have been completed. The yield improvement work for Remsima has been finished, and sequentially, cost efficiency is expected to improve with the production optimization of Truxima and Herzuma. Recorona received conditional approval in South Korea on February 5, and discussions are ongoing regarding emergency use authorization in other countries." She set Celltrion's target price at 370,000 KRW.

Over the past five days, individual investors have net purchased 490,784 shares of Celltrion, while foreign and institutional investors have net sold 203,748 shares and 278,174 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.